Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.43
-0.97 (-5.27%)
At close: Jun 27, 2025, 4:00 PM
17.43
0.00 (0.00%)
After-hours: Jun 27, 2025, 5:52 PM EDT
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 18 professional analysts, the 12-month price target for Apellis Pharmaceuticals stock ranges from a low of $18 to a high of $80. The average analyst price target of $37.67 forecasts a 116.12% increase in the stock price over the next year.
Price Target: $37.67 (+116.12%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 4 | 4 |
| Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Hold | 8 | 8 | 8 | 8 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 18 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $26 → $29 | Hold | Maintains | $26 → $29 | +66.38% | Jun 2, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $49 → $41 | Strong Buy | Maintains | $49 → $41 | +135.23% | May 22, 2025 |
| Mizuho | Mizuho | Hold Maintains $30 → $20 | Hold | Maintains | $30 → $20 | +14.74% | May 14, 2025 |
| Raymond James | Raymond James | Strong Buy → Buy Downgrades $75 → $52 | Strong Buy → Buy | Downgrades | $75 → $52 | +198.34% | May 9, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Hold Downgrades $41 → $23 | Strong Buy → Hold | Downgrades | $41 → $23 | +31.96% | May 9, 2025 |
Financial Forecast
Revenue This Year
789.26M
from 781.37M
Increased by 1.01%
Revenue Next Year
964.01M
from 789.26M
Increased by 22.14%
EPS This Year
-1.99
from -1.60
EPS Next Year
-0.67
from -1.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 931.8M | 1.2B | 1.5B | ||
| Avg | 789.3M | 964.0M | 1.2B | ||
| Low | 701.9M | 779.8M | 930.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.2% | 46.1% | 54.4% | ||
| Avg | 1.0% | 22.1% | 23.1% | ||
| Low | -10.2% | -1.2% | -3.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.47 | 1.72 | 3.03 | ||
| Avg | -1.99 | -0.67 | 0.81 | ||
| Low | -2.73 | -1.74 | -0.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.